EUVIMEDEUVIMED entdecken
Crossref

Safety, tolerability and pharmacokinetics of subcutaneous meropenem as an alternative to intravenous administration

Fionnuala Murray iD, Okhee Yoo, Samuel Brophy-Williams, Matthew Rawlins iD, Steven C Wallis iD, Jason A Roberts, Edward Raby iD, Sam Salman iD, Laurens Manning iD

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkae398 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Fionnuala Murray und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Fiona Stanley Fremantle Hospitals Group, Murdoch, Western Australia, Australia, 6150. Hauptthemen laut MEDLINE: Meropenem, Anti-Bacterial Agents, Cross-Over Studies. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Stan Perron Charitable Foundation, Australian National Health and Medical Research Council for a Centre of Research Excellence, Medical Research Future Fund Investigator.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Subcutaneous delivery of antibiotics is a practical alternative to IV administration. Meropenem is commonly used to treat infections caused by resistant Gram-negative organisms.

Methods

This was a prospective, crossover self-controlled study in 11 stable inpatients established on meropenem. Participants received a single dose of subcutaneous meropenem, in 50 mL normal saline via gravity feed. Venous blood sampling was performed at baseline, 0.5, 1, 2, 4 and 8 h following the subcutaneous and IV doses. Antibiotic concentrations were measured using UPLC-MS/MS. Pharmacokinetic data were analysed using a non-linear mixed-effects modelling approach. Pain scores and infusion site reactions (oedema/erythema) were assessed.

Results

Subcutaneous meropenem was well tolerated. The bioavailability of subcutaneous administration was 81.5% (95% CI 71.6%–93.2%). Increasing BMI was associated with slower absorption from subcutaneous tissue. Compared with IV, subcutaneous administration resulted in lower peak and higher trough concentrations. Despite the lower bioavailability observed, the PTA for free drug concentrations greater than the MIC for more than 40% of the time between doses was higher for subcutaneous than IV administration at MIC values between 0.03 and 8 mg/L. Simulated subcutaneous doses of 1.5 g twice daily, or 3 g continuous 24 h infusion had improved PTA relative to standard IV dosing of 1 g three times daily.

Conclusions

Subcutaneous meropenem appears to be well tolerated and has a favourable pharmacokinetic profile. Either 1.5 g twice daily or 3 g as a 24 h subcutaneous infusion could be considered for future evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeropenemAnti-Bacterial AgentsCross-Over StudiesHumansMaleFemaleMiddle AgedProspective StudiesInjections, SubcutaneousAdultAdministration, IntravenousAgedBiological AvailabilityTandem Mass SpectrometryThienamycinsYoung AdultMicrobial Sensitivity Tests

Substanzen

MeropenemAnti-Bacterial AgentsThienamycins

Autor:innen und Institutionen

  • Department of Infectious Diseases, Fiona Stanley Fremantle Hospitals Group, Murdoch, Western Australia, Australia, 6150.
  • Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia, 6009.
  • Pharmacy, School of Allied Health, The University of Western Australia, Perth, Western Australia, Australia, 6009.
  • Institute for Paediatric Perioperative Excellence, The University of Western Australia, Perth, Western Australia, Australia, 6009.
  • Department of Pharmacy, Fiona Stanley Fremantle Hospitals Group, Murdoch, Western Australia, Australia, 6150.
  • University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia.

ORCID-Profile: Fionnuala Murray, Matthew Rawlins, Steven C Wallis, Edward Raby, Sam Salman, Laurens Manning

Förderung

  • Stan Perron Charitable Foundation
  • Australian National Health and Medical Research Council for a Centre of Research Excellence
  • Medical Research Future Fund Investigator

Zitieren

APA

Murray, F., Yoo, O., Brophy-Williams, S., Rawlins, M., Wallis, S. C., Roberts, J. A., Raby, E., Salman, S., & Manning, L. (2025). Safety, tolerability and pharmacokinetics of subcutaneous meropenem as an alternative to intravenous administration. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae398

Vancouver

Murray F, Yoo O, Brophy-Williams S, Rawlins M, Wallis SC, Roberts JA, et al. Safety, tolerability and pharmacokinetics of subcutaneous meropenem as an alternative to intravenous administration. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkae398

BibTeX
@article{Murray2025,
  author = {Murray, Fionnuala and Yoo, Okhee and Brophy-Williams, Samuel and Rawlins, Matthew and Wallis, Steven C and Roberts, Jason A and Raby, Edward and Salman, Sam and Manning, Laurens},
  title = {Safety, tolerability and pharmacokinetics of subcutaneous meropenem as an alternative to intravenous administration},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkae398}
}
Kostenlos starten →